Q301--NEW – STX Specialized Molecular Residual Disease Testing

Special Notice Special Notice Page 3 of 3 Special Notice *= Required Field Special Notice Page 1 of 3 1. NOTICE OF INTENT DESCRIPTION The Department of Veterans Affairs, Network Contracting Office (NCO) 17, located at 5441 Babcock Road, Suite 302, San Antonio, TX 78229, intends to award an Indefinite Delivery Indefinite Quantity (IDIQ) Firm Fixed Price contract with five ordering periods on a sole-source basis to: Natera, Inc. 13011 McCallen Pass Austin, TX 78752 This requirement is for proprietary molecular genetic reference testing services used in the evaluation and monitoring of transplant patients and cancer residual disease. 2. SUPPLIES/SERVICES Item 0001 Description: Signatera Only, CPT Codes 81479, 81455 Estimated Quantity: 35 Unit: Each Item 0002 Description: Prospera, CPT Code 81479 Estimated Quantity: 25 Unit: Each Natera is the sole provider of these proprietary medical laboratory tests, including: Prospera molecular expression transplant assessment test Signatera Residual Disease Test (MRD) (non liquid biopsy tumor typing) No other vendor possesses the proprietary methodologies, assays, or intellectual property required to perform these tests. 3. SOLE SOURCE JUSTIFICATION Testing required by the VA is proprietary to Natera, Inc. No authorized distributors, third party laboratories, or alternative clinical sources exist for the Prospera and Signatera MRD tests.